Oppenheimer Reiterates Outperform on Xeris Biopharma Holdings, Raises Price Target to $21
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsReiterationPrice Target
Oppenheimer analyst Leland Gershell reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $18 to $21.
Oppenheimer analyst Leland Gershell reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $18 to $21.